국소 마취제 시장 규모, 점유율, 동향 분석 리포트 : 약제별, 용도별, 지역별, 부문 예측(2025-2030년)

Local Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine), By Application (Injectable, Surface Anesthetic), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

국소 마취제 시장의 성장과 동향 :

Grand View Research의 최신 보고서에 따르면 세계의 국소 마취제 시장 규모는 2030년까지 51억 3,000만 달러에 달할 것으로 예측됩니다.

이 시장은 2025-2030년 연평균 복합 성장률(CAGR) 3.70%를 보일 것으로 예측됩니다. 미용 수술, 치과 수술, 성형 수술 등 전 세계에서 수술 건수가 증가함에 따라 국소 마취제의 성장이 촉진되고 있습니다.

수술 후 통증 완화가 필요한 수술 건수가 크게 증가하고 있으며, 이러한 추세는 예측 기간 중 지속될 것으로 예측됩니다. 대략 전체 수술의 65.0%가 수술 후 통증 관리가 필요한 것으로 나타났습니다. 이는 국소마취제에 대한 수요를 증가시킬 것으로 예측됩니다.

레보브피바카인, 아르티카인, 로피바카인과 같은 효과적인 신약의 도입도 전 세계 국소마취제 시장의 성장을 가속하고 있습니다. 신흥 국가의 의료비 지출 증가는 인도, 중국, 브라질 등의 국가에서 수술 건수 증가로 이어질 것으로 예측됩니다. 이는 이 지역 시장 성장에 기여할 것으로 예측됩니다.

국소 마취제 시장 보고서 하이라이트

• 용도별로 시장은 주사제와 국소 마취제로 구분됩니다. 다양한 수술에 광범위하게 사용되므로 예측 기간 중 주사제 분야가 국소 마취제 시장을 지배할 것으로 예측됩니다. 약물전달 시스템의 발전은 예측 기간 중 국소 마취제 시장을 촉진할 것으로 예측됩니다.
• 북미는 수술 건수가 많아 국소마취제 시장에서 가장 큰 점유율을 차지하고 있습니다.
• 아시아태평양의 국소 마취제 산업은 급속한 도시화와 의료 인프라 개선으로 인해 예측 기간 중 가장 빠른 CAGR을 나타낼 것으로 예측됩니다.
• 약물별로는 리도카인이 2024년 28.88%의 점유율을 차지하며 시장을 독점했습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 국소 마취제 시장의 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석
  • 특허 만료 분석
  • 가격 분석

제4장 국소 마취제 시장 : 약제 비즈니스 분석

• 약제 시장 점유율, 2024년·2030년
• 약제 부문 대시보드
• 시장 규모, 예측, 동향 분석(약제별, 2018-2030년)
• Bupivacaine
• Ropivacaine
• Lidocaine
• Chloroprocaine
• Prilocaine
• Benzocaine
• 기타

제5장 국소 마취제 시장 : 용도 비즈니스 분석

• 애플리케이션 시장 점유율, 2024년·2030년
• 애플리케이션 부문 대시보드
• 시장 규모, 예측, 동향 분석(용도별, 2018-2030년)
• 주사제
• 표면 마취제

제6장 국소 마취제 시장 : 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년·2030년
• 지역 시장 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년 :
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 참가 기업 개요
• 기업의 시장 현황 분석
• 기업 분류
• 전략 지도제작
• 기업 개요/리스트
  • Johnson &Johnson Services, Inc.
  • Pfizer Inc
  • AstraZeneca
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Sanofi
  • Merck &Co., Inc.
  • Aspen Holdings
  • Viatris Inc.

KSA

영문 목차

영문목차

Local Anesthesia Drugs Market Growth & Trends:

The global local anesthesia drugs market size is anticipated to reach USD 5.13 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 3.70% from 2025 to 2030. The rising number of surgical procedures across the globe, including cosmetic surgeries, dental procedures, and plastic surgeries, is driving the growth of local anesthetics.

There has been a considerable increase in the number of surgical procedures requiring post-operative pain relief and this trend is expected to continue throughout the forecast period. Roughly, 65.0% of total surgical procedures require post-operative pain management. This is likely to boost the demand for local anesthesia drugs.

The introduction of new and effective drugs such as levobupivacaine, articaine, and ropivacaine is also driving the growth of the local anesthesia drugs market across the globe. Rising healthcare expenditure in developing countries is expected to result in an increase in the number of surgeries performed in countries such as India, China, and Brazil. This is likely to contribute to market growth in the region.

Local Anesthesia Drugs Market Report Highlights:

• By application, the market is bifurcated into injectable and surface anesthetic. The injectable segment is expected to dominate the local anesthesia drugs market during the forecast period owing to extensive usage in different surgical procedures. Advancements in drug delivery systems are expected to drive the market for surface anesthetics over the forecast period.
• North America held the largest share in the market for local anesthesia drugs owing to a significant number of surgical procedures performed in the region.
• Asia Pacific local anesthesia drugs industry is anticipated to witness the fastest CAGR over the forecast period due to rapid urbanization and improvements in healthcare infrastructure.
• By Drug segment, Lidocaine dominated the market with a 28.88% share in 2024, driven by its extensive use in injectable and topical anesthetic formulations.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Application
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Local Anesthesia Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
    • 3.3.3.1. Phase 1
    • 3.3.3.2. Phase 2
    • 3.3.3.3. Phase 3
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Local Anesthesia Drugs Market: Drug Business Analysis

• 4.1. Drug Market Share, 2024 & 2030
• 4.2. Drug Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug, 2018 to 2030 (USD Million)
• 4.4. Bupivacaine
  • 4.4.1. Bupivacaine Market, 2018 - 2030 (USD Million)
• 4.5. Ropivacaine
  • 4.5.1. Ropivacaine Market, 2018 - 2030 (USD Million)
• 4.6. Lidocaine
  • 4.6.1. Lidocaine Market, 2018 - 2030 (USD Million)
• 4.7. Chloroprocaine
  • 4.7.1. Chloroprocaine Market, 2018 - 2030 (USD Million)
• 4.8. Prilocaine
  • 4.8.1. Prilocaine Market, 2018 - 2030 (USD Million)
• 4.9. Benzocaine
  • 4.9.1. Benzocaine Market, 2018 - 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Local Anesthesia Drugs Market: Application Business Analysis

• 5.1. Application Market Share, 2024 & 2030
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Injectable
  • 5.4.1. Injectable Market, 2018 - 2030 (USD Million)
• 5.5. Surface Anesthetic
  • 5.5.1. Surface Anesthetic Market, 2018 - 2030 (USD Million)

Chapter 6. Local Anesthesia Drugs Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Local Anesthesia Drugs Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Uk Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Target Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Target Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Target Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Local Anesthesia Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Target Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Target Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Target Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Target Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Local Anesthesia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Johnson & Johnson Services, Inc.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Pfizer Inc
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. AstraZeneca
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Novartis AG
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Teva Pharmaceutical Industries Ltd.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. GSK plc
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Sanofi
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Merck & Co., Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Aspen Holdings
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Viatris Inc.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives

관련자료